SerbinCreative

(805) 963-0439 | Toll-Free (800) 876-6425

www.serbincreative.com LA / NY / UK

AtEdge

AtEdge

Photography & Motion

Directory of Illustration

Directory of Illustration

Find the world's best illustrators

PLAY! Illustration

PLAY!

Illustration for Toys & Interactive Games

Lattis Social

Social Media for the Creative Industry

More from Serbin

JavaScript may be disabled in your browser. Please enable JavaScript for access to all site features.

Home
>
Artists
>
Kryski Biomedia

Kryski Biomedia

CRYSVITA Mechanism of Action

DICERNA: Mechanism of action of GalXC RNAi therapy

medical illustration of This mechanism of action illustration explains how the CRYSVITA molecule binds to FGF23 to normalize phosphorous levels in the bloodstream. CRYSVITA (burosumab-twza) is the only FDA-approved therapy targeting the underlying cause of XLH in adults and children 6 months or older. Client: Ultragenyx Pharmaceuticals

medical illustration of This is a MOD graphic of ADA-SCID (Adenosine deaminase severe combined immune deficiency), an ultra-rare inherited genetic disorder. It is caused by a deficiency in the adenosine deaminase (ADA) enzyme and is often fatal if untreated. ADA deficiency increases the risk of severe and recurring infections by inducing apoptosis in B, T, and NK lymphocytes through toxic buildups of deoxyadenosine. Client: Leadiant Biosciences

ADA-SCID Mechanism of Disease

This mechanism of action illustration explains how the CRYSVITA molecule binds to FGF23 to normalize phosphorous levels in the bloodstream. CRYSVITA (burosumab-twza) is the only FDA-approved therapy targeting the underlying cause of XLH in adults and children 6 months or older. Client: Ultragenyx Pharmaceuticals

Keywords: Color, Design, Line with Color, Advertising / Marketing, Education, Patient Education, Professional Education, Biotechnology, Molecular Biology, Mechanism of Action (MOA)

© Diana Kryski